Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Parkinson's drug enters early human safety trials

NCT ID NCT06565195

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 38 times

Summary

This early-stage study tests an experimental drug called LY3962681 in healthy volunteers and people with Parkinson's disease. The main goal is to check safety and how the body processes the drug. Participants receive one or two injections into the spinal fluid and are followed for up to a year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Austin Clinic PPD

    RECRUITING

    Austin, Texas, 78744-1625, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ehime University Hospital

    NOT_YET_RECRUITING

    Tōon, Ehime, 791-0295, Japan

  • Oita University Hospital

    NOT_YET_RECRUITING

    Yufu, Oita Prefecture, 879-5593, Japan

  • P-One Clinic, Keikokai Medical Corporation

    RECRUITING

    Hachiōji, Tokyo, 192-0071, Japan

Conditions

Explore the condition pages connected to this study.